Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Nasopharyngeal Carcinoma 8Esophageal Squamous Cell Carcinoma 6Carcinoma, Non-Small-Cell Lung 6Squamous Cell Carcinoma of Head and Neck 5Small Cell Lung Carcinoma 5Triple Negative Breast Neoplasms 4Recurrence 3Pancreatic Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Neoplasm Metastasis 2Muscle Invasive Bladder Cancer (MIBC) 2Biliary Tract Neoplasms 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Sarcoma 1Salivary Gland Malignant Neoplasms 1SCLC, Extensive Stage 1Rectal Neoplasms 1Rare Tumour 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non-Muscle Invasive Bladder Neoplasms 1Non Squamous Non Small Cell Lung Cancer 1Neoplasms 1NSCLC 1Muscle-invasive Bladder Urothelial Carcinoma 1Melanoma 1Esophageal Neoplasms 1

Interventions

toripalimab 1Mitomycin 1Gemcitabine 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma in Situ × toripalimab × Clear all
NCT07189793 2025-09-24

OHAI-NMIBC-01

First Affiliated Hospital of Wenzhou Medical University

Phase 2 Not yet recruiting
106 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡